Bharat Immunologica And Bio Corp share price
You have to be logged in to add this to Watchlist.- ₹21.91(1.06%)March 21, 2025 15:55:58 PM IST
- NSE
- BSE
- Vol : 41.55K (NSE + BSE)Last 20 day avg : 56.87 K
Bharat Immunologica And Bio Corp is trading 1.06% upper at Rs 21.91 as compared to its last closing price. Bharat Immunologica And Bio Corp has been trading in the price range of 22.50 & 21.80. Bharat Immunologica And Bio Corp has given -8.68% in this year & 0.37% in the last 5 days. The company posted a net profit of -4.92 Crores in its last quarter.Listed peers of Bharat Immunologica And Bio Corp include Pharmaids Pharmaceuticals Ord B (3.17%), Welcure Drugs And Pharmaceutic Ord T (1.93%), Bharat Immunologica And Bio Corp (1.06%).The Mutual Fund holding in Bharat Immunologica And Bio Corp was at -% in . The MF holding has - from the last quarter. The FII holding in Bharat Immunologica And Bio Corp was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 21, 2025, 02:11 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BLower than historical values1.07The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values0.00Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility3.26Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.80The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is not profitable- The company's revenue fell during September quarter by 100.00% from Rs 26.48 crore to Rs 0.00 crore, year-on-year
- The company has increased its September quarter loss by 59.52% from Rs 3.08 crore to Rs 4.92 crore, year-on-year
- The debt to equity of the company is higher than the industry median
- Earnings are insufficient to cover the interest expenses on outstanding debt
- R1
- 25.49
- R2
- 27.75
- R3
- 30.49
- S1
- 20.49
- S2
- 17.75
- S3
- 15.49
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Pharmaids Pharmaceuticals Ord B | Bullish | 69.60 | 3.17 | 245.46 | - | 3.34 | - | 8.40 |
| Welcure Drugs And Pharmaceutic Ord T | Bullish | 10.03 | 1.93 | 112.85 | - | 9.73 | - | - |
| Bharat Immunologica And Bio Corp | Moderately Bearish | 21.91 | 1.06 | 94.61 | - | 1.08 | - | - |
| Makers Laboratories Ord B | Moderately Bearish | 138.95 | 0.36 | 81.99 | - | 1.28 | - | 16.94 |
| Ind Swift Ord T | Neutral | 14.43 | -0.35 | 78.16 | 4.10 | - | - |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2024-08-16 | General Purpose. |
| 2024-03-08 | Others |
| 2023-10-31 | Quarterly Results |
| 2023-04-24 | Audited Results |
| 2023-02-09 | Quarterly Results |
- IndustryMajor Drugs
- ISININE994B01014
- BSE Code524663
- NSE Code
Bharat Immunologica And Bio Corp is trading at 21.91 as on Fri Mar 21 2025 10:25:58. This is 1.06% upper as compared to its previous closing price of 21.68.
The market capitalization of Bharat Immunologica And Bio Corp is 94.61 Cr as on Fri Mar 21 2025 10:25:58.
The 52 wk high for Bharat Immunologica And Bio Corp is 35.88 whereas the 52 wk low is 19.00
Bharat Immunologica And Bio Corp can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: 27.82
- Dividend Yield: 0.00%
- D/E ratio: 0.96
Bharat Immunologica And Bio Corp reported a net profit of -17.06 Cr in 2023.